JournalScan
| The first 150 words of the full text of this article appear below. |
ISCHAEMIC HEART DISEASE
The use of sirolimus-eluting and paclitaxel-eluting stents in the treatment of de novo coronary lesions has not been compared in a prospective multicentre study to date. In the REALITY trial, 1386 patients from 90 hospitals across Europe, Latin America and Asia were randomly assigned to receive either a sirolimus-eluting (n = 701) or a paclitaxel-eluting stent (n = 685). All patients had angina pectoris and one or two de novo native coronary artery lesions in vessels of between 2.25–3.00 mm in diameter. Angiographic follow up was performed at eight months and clinical follow up at 12 months. The primary end point was in-lesion binary restenosis (defined as a luminal stenosis of more than 50%) at eight months. Secondary end points included one year rates of target lesion and vessel revascularisation and a composite end point of cardiac death, Q wave or non-Q wave myocardial infarction, coronary artery bypass grafting, or
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
- Full Text
- Full Text (PDF)
- Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
Services
- Email this link to a friend
- Similar articles in this journal
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Bookmark with
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
